

me

0420
See date 8/27/01
#2
m.s.
9/20/01
W. Affleck

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Kapin et al.


U.S. Serial No. 09/929,381


Filed: August 13, 2001

Examiner: NYA

Group Art Unit:

For: Method of Treating Angiogenesis-
Related Disorders



CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:	
Date	August 29, 2001
	
	Jeannie Burke

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56. Applicants submit the following patents, articles and other information:

U.S. Patent No. 3,828,093, Bays et al., issued August 6, 1974, for "Benzoylphenylacetic Acids and Related Compounds"

U.S. Patent No. 4,045,576, Welstead, Jr. et al., issued August 30, 1977, for "Anti-Inflammatory Methods Using 2-amino-3-(5- and 6-)Benzoylphenylacetic Acids, Esters and Metal Salts Thereof and the Compounds"

U.S. Patent No. 4,126,635, Welstead, Jr. et al., issued November 21, 1978, for "2-Amino-3-(5- and 6-)Benzoylphenylacetic Acids, Esters and Metal Salts Thereof"

U.S. Patent No. 4,182,774, Welstead, Jr. et al., issued January 8, 1980, for "Method of Inhibiting Blood Platelet Aggregation with 2-Amino-3-(5- and 6-) Benzoylphenylacetic Acids, Esters and Metal Salts Thereof"

U.S. Patent No. 4,254,146, Walsh, issued March 3, 1981, for "3-Benzoyl-2-Nitrophenylacetic Acids, Metal Salts, Amides and Esters"

U.S. Patent No. 4,313,949, Shanklin, Jr. et al., issued February 2, 1982, for "Method of Producing an Inhibitory Effect on Blood Platelet Aggregation"

U.S. Patent No. 4,454,151, Waterbury, issued June 12, 1984, for "Use of Pyrrolo Pyrroles in Treatment of Ophthalmic Diseases"

U.S. Patent No. 4,503,073, Walsh et al., issued March 5, 1985, for "2-Amino-3-(Alkylthiobenzoyl)-Phenylacetic Acids"

U.S. Patent No. 4,568,695, Moran et al., issued February 4, 1986, for "2-Amino-3-Benzoyl-Phenethylalcohols and Intermediates Therefor"

U.S. Patent No. 4,683,242, Poser, issued July 28, 1987, for "Transdermal Treatment for Pain and Inflammation with 2-Amino-3-Aroylbenzeneacetic Acids, Salts and Esters"

U.S. Patent No. 4,783,487, Brune, issued November 8, 1988, for "N-(1-Carboxy-2-Hydroxy-5-Phenyl)-2-(6-Methoxy-2-Naphthyl)Propionamide and Anti-inflammatory Use Thereof"

U.S. Patent No. 4,851,443, Brune, issued July 25, 1989, for "Carboxylic Acid Amides, Compositions and Medical Use Thereof"

U.S. Patent No. 4,910,225, Ogawa et al., issued March 20, 1990, for "Locally Administrable Therapeutic Composition for Inflammatory Disease"

U.S. Patent No. 5,073,641, Bundgaard et al., issued December 17, 1991, for "Prodrug Derivatives of Carboxylic Acid Drugs"

U.S. Patent No. 5,314,909, Dollerup, issued May 24, 1994, for "Use of Non-Steroidal Anti-inflammatory Agents in Macular Degeneration"

U.S. Patent No. 5,475,035, Yanni et al., issued December 12, 1995, for "Topically Administrable Compositions Containing 3-Benzoylphenylacetic Acid Derivatives for Treatment of Ophthalmic Inflammatory Disorders"

U.S. Patent No. 6,025,353, Masferrer et al., issued February 15, 2000, for "Method of Using Cyclooxygenase-2 Inhibitors as Anti-angiogenic Agents"

U. S. Patent No. 6,066,671, Yanni et al., issued May 23, 2000, for "Treatment of GLC1A Glaucoma with 3-Benzoyl-Phenylacetic Acids, Esters, or Amides"

U.S. Patent No. 6,069,139, Kuriyama et al., issued May 30, 2000, for "Method and Composition for Prophylaxis and Treatment of Retinal Diseases"

EP 1 064 949 A2, Mylari, published January 3, 2001, for "Compositions Containing Aldose Reductase Inhibitors and Selective Cyclooxygenase Inhibitors for the Treatment of Diabetic Complications"

EP 1 064 964 A2, Mylari, published January 3, 2001, for "Compositions Containing Aldose Reductase Inhibitors and Selective Cyclooxygenase Inhibitors for the Treatment of Diabetic Complications"

EP 1 064 965 A2, Mylari, published January 3, 2001, for "Combinations of Aldose Reductase Inhibitors and Selective Cyclooxygenase-2 Inhibitors"

UK 2 071 086 A, Welstead et al., published September 16, 1981, for "2-Amino-3-[Hydroxy(phenyl)-methyl]phenylacetic acids, esters and amides"

UK 2 093 027 A, Walsh et al., published August 25, 1982 for "2-Amino-3-(halobenzoyl)-methylphenylacetic acids, esters and salts thereof"

WO 00/40087, Kalgutkar et al., published July 13, 2000, for "Converting Cox Inhibition Compounds That are Not Cox-2 Selective Inhibitors to Derivatives That are Cox-2 Selective Inhibitors"

Clark et al., "Ocular Angiostatic Agents," *Exp. Opin. Ther. Patents*, Volume 10(4), pp. 427-448 (2000)

Gamache et al., "Nepafenac, A Unique Nonsteroidal Anti-Inflammatory Prodrug With Potential Utility In The Treatment Of Trauma-Induced Acute Ocular Inflammation," *Investigative, Ophthalmology. And Visual. Science, The Association for Research in Vision and Ophthalmology*, Vol. 41(4):1892 (2000)

Gamache et al., "Nepafenac, A Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: I. Assessment of Anti-Inflammatory Efficacy," *Inflammation*, Vol 24(4); pp. 357-370 (2000)

Graff et al., "In Vitro Characterization of the Ocular Bioactivation and Permeation of External Ocular Barriers of Nepafenac, a Potent Topical Ocular NSAID with Long Duration of Action," *Investigative, Ophthalmology. And Visual. Science, The Association for Research in Vision and Ophthalmology*, Vol. 41(4):1892 (2000)

Kapin et al., "Inhibition of Concanavalin-A Mediated Pan Retinal Edema By Nepafenac," *Investigative, Ophthalmology. And Visual. Science, The Association for Research in Vision and Ophthalmology*, Vol. 41(4):1887 (2000)

Ke et al. "Nepafenac, A Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: II. In Vitro Bioactivation and Permeation of External Ocular Barriers," *Inflammation*, Vol. 24(4), pp. 371-384 (2000)

Rawji et al., "Quantification of Concanavalin-A Mediated Retinal Edema Using Scanning Laser Tomography Derived Edema Maps," *Investigative, Ophthalmology. And Visual. Science, The Association for Research in Vision and Ophthalmology*, Vol. 41(4):871 (2000)

Sancilio et al., "AHR-10037, a non-steroidal anti-inflammatory compound of low gastric toxicity," *Agents and Actions*, Vol. 31(1/2), pp. 117-126 (1990)

Walsh et al., "Antiinflammatory Agents. 4. Syntheses and Biological Evaluation of Potential Prodrugs of 2-Amino-3-benzoylbenzeneacetic Acid and 2-Amino-3-(4-chlorobenzoyl)benzeneacetic Acid," *J. Med. Chem.*, Vol. 33, pp. 2296-2304 (1990)

Walsh et al., "Antiinflammatory Agents. 3. Syntheses and Pharmacological Evaluation of 2-Amino-3-benzoylphenylacetic Acid and Analogues," *J. Med. Chem.*, Vol. 27(11), pp. 1379-1388 (1984)

For the convenience of the Examiner, the patents and articles are also listed on PTO Form 1449.

The Examiner's attention is brought to co-pending U.S. Serial No. 09/929,704. A copy is not enclosed herewith since it is readily available.

Applicants request that the listed references be considered during prosecution of this application, and that the references appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,
ALCON

August 29, 2001
Date

Patrick M. Ryan
Patrick M. Ryan
Registration No. 36,263

U.S. Serial No. 09/929,381
Filed: August 13, 2001

Alcon Universal Ltd.
c/o Alcon Research, Ltd.
R&D Counsel Q-148
6201 South Freeway
Fort Worth, Texas 76134-2099
(817) 551-3066

Attorney Docket No.: 1973